补充镁对因抗表皮生长因子受体（EGFR）抗体导致低镁血症的癌症患者的疗效：一项系统评价
Efficacy of Magnesium Supplementation in Cancer Patients Developing Hypomagnesemia Due to Anti-EGFR Antibody: A Systematic Review.
作者信息
Kato Taigo, Kawaguchi Takahisa, Funakoshi Taro, Fujiwara Yutaka, Yasuda Yoshinari, Ando Yuichi
机构信息
Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.
Department of Nephrology, Kawasaki Municipal Kawasaki Hospital, Kanagawa, Japan.
出版信息
Cancer Diagn Progn. 2024 Jul 3;4(4):390-395. doi: 10.21873/cdp.10337. eCollection 2024 Jul-Aug.
BACKGROUND/AIM: Hypomagnesemia is a common side effect of anti-epidermal growth factor receptor (EGFR) antibodies, which may lead to arrhythmia. However, there are no evidence-based guidelines for magnesium (Mg) supplementation in the management of hypomagnesemia in patients with anti-EGFR antibodies. Therefore, we performed a systematic review to address clinical questions regarding these cancer patients.
MATERIALS AND METHODS
Three electronic databases were searched for articles published until June 18, 2021. The main outcomes used were "anti-EGFR antibody" and "hypomagnesemia".
RESULTS
After screening 78 references in PubMed, Cochrane Library, and ICHUSHI-web databases, three studies were included in the review. One study revealed the effectiveness of Mg supplementation in the management of hypomagnesemia in patients receiving cetuximab. However, no studies have investigated whether correcting hypomagnesemia can lead to the suppression of arrhythmias as a clinical outcome.
CONCLUSION
Weak evidence suggests that Mg supplementation, as a preventive measure when developing hypomagnesemia following the initiation of anti-EGFR antibody therapy, may prevent the worsening of hypomagnesemia, and subsequently prevent associated arrhythmia occurrence.
背景/目的：低镁血症是抗表皮生长因子受体（EGFR）抗体的常见副作用，可能导致心律失常。然而，在抗EGFR抗体治疗的患者中，对于低镁血症的管理，目前尚无基于证据的镁（Mg）补充指南。因此，我们进行了一项系统评价，以解决有关这些癌症患者的临床问题。
材料与方法
检索了三个电子数据库中截至2021年6月18日发表的文章。主要的检索词为“抗EGFR抗体”和“低镁血症”。
结果
在对PubMed、Cochrane图书馆和ICHUSHI网络数据库中的78篇参考文献进行筛选后，本评价纳入了三项研究。一项研究显示补充镁对接受西妥昔单抗治疗的患者低镁血症的管理有效。然而，尚无研究调查纠正低镁血症是否能作为临床结局导致心律失常的抑制。
结论
证据不足表明，在开始抗EGFR抗体治疗后出现低镁血症时，补充镁作为一种预防措施，可能预防低镁血症的恶化，并随后预防相关心律失常的发生。
Zotero 插件